Important note

This AI stock analysis for TC BioPharm is not up to date. Creating and accessing our AI stock Analysis (powered by our data and Chat GPT) is only available for our premium users. Sign up to get access today!

TC BioPharm - AI Stock Analysis

Analysis generated April 15, 2025

TC BioPharm is a biotechnology company focused on developing and commercializing cell-based immunotherapy products. Operating in a highly competitive and research-intensive sector, the firm has been dedicated to novel therapeutic approaches aimed at treating cancer and other immune-related diseases. Despite its cutting-edge pursuits, the company has faced challenges in revenue generation and market performance.

Fundamental Analysis

In the latest quarter, TC BioPharm reported a revenue of $0. This figure is consistent with the preceding quarter and the same quarter last year, showing stability in its revenue stream, albeit stagnant. More promisingly, the net income for the last quarter stood at $2M, marking a substantial increase of 39.14% compared to the previous quarter. However, this favorable growth is overshadowed by a significant 216.33% decrease when compared to the same quarter last year, signaling potential underlying issues.

The Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) also exhibited growth, with a last-quarter figure of $2M. This represents a 40.45% increase from the previous quarter and a 50.84% rise compared to the same quarter last year, indicating a positive trajectory in operational efficiency and potential profitability.

Technical Analysis

The current stock price of TC BioPharm stands at $0.50. Over the past month, the stock price has plummeted by 71.10%, raising concerns regarding short-term investor confidence and market sentiment. Looking at a longer-term perspective, the stock price has decreased by a staggering 99.63% over the past year, which is quite alarming and may indicate deep-rooted issues within the company.

From a trend analysis standpoint, the stock demonstrates neutrality with a current Simple Moving Average (SMA10) of 0.50, which matches the previous SMA10. The Relative Strength Index (RSI) is currently at 58.3, indicating a neutral market condition without any apparent overbought or oversold signals.

Alternative Data Analysis

Analyzing alternative data reveals further insights into the company's current status. TC BioPharm has maintained zero open job positions, which could indicate stability but also a potential halt in expansion or development activities. In terms of customer acquisition, estimated webpage visitors have declined by 69% over the past couple of months, a troubling trend suggesting a drop in customer interest or engagement.

Social media metrics also paint a static picture, with TC BioPharm's Twitter following stable at 930 without noticeable fluctuation in recent months. Additionally, the AltIndex’s AI score for TC BioPharm stands at 49, implying a hold signal. This score integrates fundamental, technical, and alternative data, providing a holistic view of the stock's prospects.

Conclusion

TC BioPharm exhibits a mixed bag of performance metrics. On the one hand, the company has shown positive signs of growth in net income and EBITDA in the recent quarter compared to the immediate past quarter, indicating some favorable developments. On the other hand, stagnant revenue figures and a drastic year-over-year drop in net income are red flags that need to be addressed.

The stock price has been on a significant downtrend, which is a major concern for current and potential investors. Alternative data further supports a cautious stance, with declining website traffic and static social media engagement underscoring potential issues in customer acquisition and market interest.

Considering all the available data, the recommendation for TC BioPharm would be to hold. This implies monitoring the stock for any further developments or signs of potential recovery before making any decisive investment moves.

Disclaimer: This AI stock analysis, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current.